Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5279744
Max Phase: Preclinical
Molecular Formula: C48H61FO14
Molecular Weight: 881.00
Associated Items:
ID: ALA5279744
Max Phase: Preclinical
Molecular Formula: C48H61FO14
Molecular Weight: 881.00
Associated Items:
Canonical SMILES: CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](O[C@H]2CC[C@]34C[C@]35CC(=O)[C@]3(C)[C@H]6[C@H](C)C[C@]7(OC(OC(=O)c8ccccc8F)[C@@]8(C)O[C@@H]78)O[C@H]6C[C@@]3(C)[C@@H]5CC[C@H]4C2(C)C)OC[C@H]1OC(C)=O
Standard InChI: InChI=1S/C48H61FO14/c1-23-18-48(40-45(9,62-40)41(63-48)60-38(54)27-12-10-11-13-28(27)49)61-29-19-43(7)32-15-14-31-42(5,6)34(16-17-46(31)22-47(32,46)20-33(53)44(43,8)35(23)29)59-39-37(58-26(4)52)36(57-25(3)51)30(21-55-39)56-24(2)50/h10-13,23,29-32,34-37,39-41H,14-22H2,1-9H3/t23-,29+,30-,31+,32+,34+,35+,36+,37-,39+,40-,41?,43+,44-,45+,46-,47+,48-/m1/s1
Standard InChI Key: DOYMAOAUBPJMJV-CJLABLRQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 881.00 | Molecular Weight (Monoisotopic): 880.4045 | AlogP: 6.38 | #Rotatable Bonds: 7 |
Polar Surface Area: 171.72 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 0 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 6.83 | CX LogD: 6.83 |
Aromatic Rings: 1 | Heavy Atoms: 63 | QED Weighted: 0.13 | Np Likeness Score: 2.09 |
1. Zhang H, Chen Y, Huang S, Xiao WW, Qiu MH, Shao LD, Chen CH, Li D.. (2023) Development of actein derivatives as potent anti-triple negative breast cancer agents., 89 [PMID:37121522] [10.1016/j.bmcl.2023.129307] |
Source(1):